Related Articles
Genetic alterations in epidermal growth factor receptor‑tyrosine kinase inhibitor‑naïve non‑small cell lung carcinoma
Randomized phase II study of sequential carboplatin plus paclitaxel and gefitinib in chemotherapy‑naïve patients with advanced or metastatic non‑small‑cell lung cancer: Long‑term follow‑up results
Heterozygous mutation (G/G→G/A) at nt 2607 of the EGFR gene is closely associated with increases in EGFR copy number and mRNA half life, but impaired EGFR protein synthesis in squamous cell carcinomas of the head and neck – implication for gefitinib efficacy
Mutations of the epidermal growth factor receptor gene in NSCLC patients
EGFRvIII mutation in lung cancer correlates with increased EGFR copy number